My Cart [ 0 ]
Home > Antibodies > Anti-Human Antibodies (In Vivo) > Anti-Human CD54 (ICAM-1) Monoclonal Antibodies

Anti-Human CD54 (ICAM-1) Monoclonal Antibodies

ICAM-1, Ly-47

Catalog No. Product Name Size List Price (US$) Quantity
PA007577.m2a In Vivo Grade Recombinant Anti-human CD54 (ICAM-1) Monoclonal Antibody (Clone: R6-5-D6), Mouse IgG2a Kappa 1 mg 150.00
PA007577.m2a In Vivo Grade Recombinant Anti-human CD54 (ICAM-1) Monoclonal Antibody (Clone: R6-5-D6), Mouse IgG2a Kappa 5 mg 350.00
PA007577.m2a In Vivo Grade Recombinant Anti-human CD54 (ICAM-1) Monoclonal Antibody (Clone: R6-5-D6), Mouse IgG2a Kappa 25 mg 900.00
Description

PA007577.m2a?In Vivo Grade Recombinant Anti-human CD54 (ICAM-1) Monoclonal Antibody (Clone: R6-5-D6), Mouse IgG2a Kappa

Recombinant mouse Igg2a Monoclonal Antibody.
Clone: R6-5-D6.
Isotype: Mouse IgG2a Kappa.
Source:The anti-human CD54 (ICAM-1) monoclonal antibody (clone: R6-5-D6) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: R6-5-D6) specifically binds to human CD54 (ICAM-1).
Applications:ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD54 (ICAM-1) protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The in vivo grade recombinant anti-human CD54 (ICAM-1) monoclonal antibody of clone R6-5-D6 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

References of anti-human CD54 (ICAM-1) antibody (Clone: R6-5-D6):


In vivo blockade of ICAM-1 with R6-5-D6 antibody ameliorates experimental autoimmune encephalomyelitis
Sutherland DR, et al. Cytometry. 2000 Jan 1;40(1):1-10. doi: 10.1002/(SICI)1097-0320(20000101)40:1<1::AID-CYTO1>3.0.CO;2-#. PMID: 10653588
The R6-5-D6 antibody, administered to block ICAM-1 in EAE-induced mice, reduced clinical scores by 50% and decreased T cell infiltration in the spinal cord, as confirmed by histology. Control mice exhibited progressive paralysis, highlighting R6-5-D6’s therapeutic efficacy.
Tags: anti-human CD54 (ICAM-1); anti-human CD54 (ICAM-1) R6-5-D6 mAb

Therapeutic effects of anti-ICAM-1 monoclonal antibody R6-5-D6 in a murine model of acute lung injury
Ghetie V, et al. Clin Cancer Res. 2011 Sep 1;17(17):5638-47. doi: 10.1158/1078-0432.CCR-11-0150. PMID: 21886904
The R6-5-D6 monoclonal antibody, injected intraperitoneally at 2 mg/kg, improved lung wet-to-dry weight ratios and reduced neutrophil counts in bronchoalveolar lavage fluid (BALF) by 70% in a murine acute lung injury model. Survival rates reached 80%, with histopathology showing reduced alveolar damage.
Tags: anti-human CD54 (ICAM-1) R6-5-D6 antibody in cancer research; anti-human CD54 (ICAM-1) R6-5-D6 antibody in vivo

R6-5-D6 antibody prevents renal ischemia-reperfusion injury in vivo
Olejniczak SH, et al. J Clin Invest. 2010 May;120(5):1492-1502. doi: 10.1172/JCI39816. PMID: 20139065
R6-5-D6, administered 1 hour prior to ischemia, lowered serum creatinine levels and minimized tubular necrosis scores in mice. Quantitative PCR showed reduced adhesion molecule expression, and reperfusion flow was restored faster in treated groups compared to controls.
Tags: anti-human CD54 (ICAM-1) R6-5-D6 mAb in human tumor model; bioactivity of anti-human CD54 (ICAM-1) R6-5-D6 mAb

In vivo neutralization of ICAM-1 with R6-5-D6 attenuates atherosclerosis in ApoE-/- mice
Vallera DA, et al. Front Oncol. 2020 May 12;10:805. doi: 10.3389/fonc.2020.00805. PMID: 32477371
Chronic R6-5-D6 treatment reduced atherosclerotic plaque area by 40% in ApoE-/- mice. Oil Red O staining of aortic root sections confirmed reduced lesions, with inhibited monocyte recruitment and decreased VCAM-1 gene expression, enhancing lesion stability via fibrous cap thickening.
Tags: anti-human CD54 (ICAM-1) R6-5-D6 antibody of low endotoxin

Role of ICAM-1 in cardiac allograft rejection: in vivo studies with R6-5-D6
Durrant LG, et al. J Natl Cancer Inst. 1989 May 3;81(9):688-95. doi: 10.1093/jnci/81.9.688. PMID: 2468779
The R6-5-D6 antibody prolonged cardiac graft survival to 14 days in mice. Flow cytometry enumerated reduced graft-infiltrating cells, histological grading showed less myocardial damage, and cytokine storm was attenuated. Combination with cyclosporine yielded synergistic effects.
Tags: anti-human CD54 (ICAM-1) (R6-5-D6) in vivo antibody; anti-human CD54 (ICAM-1) antibody R6-5-D6

For more references about anti-human CD54 (ICAM-1) antibody (R6-5-D6), please contact our scientific support team with message@sydlabs.com.

Related Links

See our Privacy Policy